This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (August 2018) |
Koronis Pharmaceuticals is a Seattle area biotechnology company founded in 1998. Koronis is dedicated to the development of antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV) infection. The company also has products in development for the treatment of hepatitis C and RSV infection.
| Industry | Biotechnology |
|---|---|
| Founded | 1998 |
References
edit- Hirschler, Ben, "U.S. HIV drug firm Koronis looks to London listing", Reuters
- Cook, John (June 28, 2007), "Koronis' HIV drug draws funding; $20 million to be used for studies", Seattle P-I
- Dolan, Kerry A. (July 20, 2011), "Embracing The Enemy", Forbes
- Cook, John (August 2, 2005), "Biotech pioneer Gillis ventures into a new field", Seattle P-I
- Paulson, Tom. "Conflicts Advance a Burgeoning Field Industry, Academia Now are Bedfellows." Seattle P-I. May 19, 1999: A1.
- Biotech Industry Driven By Evolution Searching For Cures, Companies Get Creative. Carol Smith P-I Reporter. Seattle P-I. May 17, 1999: A1.
- Mature companies beat out new ones for VC cash. Romano, Benjamin J. Seattle Times. October 25, 2005: C1.
- Specter, Michael (December 3, 2007), "Darwin's Surprise", The New Yorker, vol. 83, no. 38, pp. 64–
- Mone, Gregory (February 2009), "The new virus killer: scientists try to turn HIV's greatest strength--mutation--against itself.", Popular Science, vol. 274, no. 2, pp. 27–
External links
edit- Official website
- Reuters story on IPO prospects [1]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |